Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say - Reuters
Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
All Coverage
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxPbmV4NWgtNHIxcFNOYk8tdEdrZVQ2cmdKQUJsWG12bUszbXVLN3NJZWo1VnowM0NocTVPb3RtQ2dSWE5JeXJiRnF4RkR4LVlGcEtrZHRTWUxnS3UyajM3QUlUbDVhZ0pqZWdCSE5QRS1QTE9BekIyTlF2OFZqZFF0SHZCaHZVTHZ3amRfd3VUdGZUSUlsQm9jZDg5M3FHaDBDdGFkc1hFM0t3U1N6SkxvamppdUMyVmFicHA0VDZDSQ?oc=5" target="_blank">Exclusive: Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say</a> <font color="#6f6f6f">Reuters</font>
Inhibrx Biosciences is exploring a joint spin-off of its experimental cancer drug, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The potential valuation of the drug could exceed $8 billion if clinical trials confirm its efficacy.
Merck & Co, Germany's Merck KGaA, and Japan's Ono Pharmaceutical are reportedly interested in Inhibrx's experimental cancer treatment, INBRX-106, which is being tested alone and in combination with Merck's Keytruda. The drug could be valued at over $8 billion if clinical trials are successful.
Similar Stories
Related coverage based on topic and tags
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports - Reuters
AstraZeneca, Daiichi near UK pricing deal for breast cancer drug, Bloomberg News reports Reuters
July 8, 2026 at 06:34 PMGSK, Hansoh's targeted cancer drug hits main survival goal in China trial - Reuters
GSK, Hansoh's targeted cancer drug hits main survival goal in China trial Reuters
July 10, 2026 at 01:46 PMGSK's Jemperli meets main goal in mid-stage rectal cancer trial - Reuters
GSK's Jemperli meets main goal in mid-stage rectal cancer trial Reuters
July 13, 2026 at 06:45 PMUS FDA approves Celcuity's breast cancer drug - Reuters
US FDA approves Celcuity's breast cancer drug Reuters
July 14, 2026 at 10:36 PMUS FDA approves Sanofi's wearable injector form of blood cancer drug - Reuters
US FDA approves Sanofi's wearable injector form of blood cancer drug Reuters
July 10, 2026 at 05:49 PMWarburg Pincus nears $7 billion deal for PANTHERx Rare, WSJ reports - Reuters
Warburg Pincus nears $7 billion deal for PANTHERx Rare, WSJ reports Reuters
July 10, 2026 at 05:35 PM